Presentation to Discuss Correlation Between
Use of High-Frequency (10 kHz) Spinal Cord Stimulation and
Reductions in HbA1c and Body Weight
Nevro to Participate in ADA's Painful Diabetic
Neuropathy Symposium and Host Product Theater Presentation
REDWOOD
CITY, Calif., June 23,
2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a
global medical device company that is delivering comprehensive,
life-changing solutions for the treatment of chronic pain, today
announced that data from an analysis of the 24-Month SENZA Painful
Diabetic Neuropathy (PDN) Randomized Controlled Trial (RCT), the
largest RCT to evaluate spinal cord stimulation (SCS) to treat PDN,
will be presented at the American Diabetes Association (ADA) 83rd
Scientific Sessions to be held June 23-26,
2023 in San Diego, CA.
Nevro will present important secondary findings from the
landmark SENZA-PDN RCT that compared Nevro's proprietary,
high-frequency (10 kHz) SCS plus Conventional Medical Management
(CMM) for the treatment of PDN to CMM alone. The presentation of
secondary data will be the first look at the correlation between
the use of a 10 kHz SCS implant and reductions in HbA1c (A1C) and
body weight. These results are also summarized in an ADA abstract
entitled "Painful Diabetic Neuropathy: Patients Treated with
High-Frequency (10 kHz) Spinal Cord Stimulation (SCS) Experience
Significant Reductions in A1C and Weight."
"Nevro continues to lead the way in the development of robust
clinical data for the use of 10 kHz Therapy™ for patients
suffering from chronic pain and PDN," stated Kevin Thornal, CEO and President of Nevro.
"Previously reported profound pain relief and sensory improvement,
coupled with reductions in A1C and weight reported here, further
demonstrate the benefits of 10 kHz SCS treatment in the
comprehensive care of patients with PDN."
Nevro HFX™ will be featured during an ADA product theater
presentation by Dr. David C. Klonoff
and Dr. Erika Petersen and during an
invited presentation by Dr. Erika
Petersen in an ADA symposium on the treatment of painful
diabetic neuropathy. Nevro will showcase the company's HFX platform
of SCS solutions in Exhibit Booth #1225.
Details for the product theater and symposium presentations are
below:
ADA Product Theater Presentation: Pathophysiological
Impact of Nevro HFX™ High Frequency (10 kHz) Spinal Cord
Stimulation for Painful Diabetic
Neuropathy
- Presenters: Dr. David C.
Klonoff; Dr. Erika
Petersen
- Date & Time: Sunday, June 25,
2023 at 10:15-11:00 AM PT
- Location: Exhibit Floor, Product Theater 2
ADA Symposium: What Is the Best Approach to the Management
of Painful Diabetic Neuropathy?
- Presenter: Dr. Erika
Petersen
- Date & Time: Monday, June 26,
2023 at 1:30-3:00 PM PT
- Location: Room 24
Only registered attendees of the ADA Scientific Sessions will be
able to access the product theater presentation and the exhibit
hall.
About Painful Diabetic Neuropathy (PDN)
The World Health Organization estimates 422 million adults live
with diabetes worldwide and the prevalence (8.5%) has nearly
doubled over four decades.1 Diabetes may cause
systemic damage with profound impact on health-related quality of
life and is potentially life-threatening. Diabetic peripheral
neuropathy is a common complication presenting as pain and other
dysesthesias, including numbness, burning, or tingling.
Approximately 20% of patients with diabetes will develop painful
diabetic neuropathy (PDN), a progressive, potentially debilitating
chronic neuropathic pain condition.2 In the U.S.,
it is estimated that there are approximately 140,000 to 200,000 PDN
patients each year that become refractory to conventional medical
management, representing an annual total addressable market
opportunity of approximately $3.5
billion to $5.0
billion.3,4
About the ADA Scientific Sessions
The American Diabetes Association's Scientific Sessions offer
researchers and health care professionals from around the globe an
exclusive opportunity to share ideas and gain knowledge about the
recent advances in diabetes research, treatment, and care.
Attendees will have access to more than 3,000 original research
presentations, take part in thought-provoking speaking engagements
with leading diabetes experts, and expand their professional
networks. For more information, please visit the ADA Website:
https://professional.diabetes.org/scientific-sessions.
Internet Posting of Information
Nevro routinely posts information that may be important to
investors in the "Investor Relations" section of its website at
www.nevro.com. The company encourages investors and potential
investors to consult the Nevro website regularly for important
information about Nevro.
About Nevro
Headquartered in Redwood City,
California, Nevro is a global medical device company focused
on delivering comprehensive, life-changing solutions that continue
to set the standard for enduring patient outcomes in chronic pain
treatment. The company started with a simple mission to help more
patients suffering from debilitating pain and developed its
proprietary 10 kHz Therapy™, an evidence-based, non-pharmacologic
innovation that has impacted the lives of more than 100,000
patients globally. Nevro's comprehensive HFX™ spinal cord
stimulation (SCS) platform includes a Senza SCS system and support
services for the treatment of chronic pain of the trunk and limb
and painful diabetic neuropathy.
Senza®, Senza II®, Senza Omnia™, and HFX iQ™ are the only SCS
systems that deliver Nevro's proprietary 10 kHz Therapy™. Nevro's
unique support services provide every patient with an HFX Coach™
throughout their pain relief journey and every physician with HFX
Cloud™ insights for enhanced patient and practice management.
SENZA, SENZA II, SENZA OMNIA, OMNIA, HF10, the HF10 logo, 10 kHz
Therapy, HFX, the HFX logo, HFX iQ, the HFX iQ logo, HFX Algorithm,
HFX CONNECT, the HFX Connect logo, HFX ACCESS, the HFX Access logo,
HFX COACH, the HFX Coach logo, HFX CLOUD, the HFX Cloud logo,
RELIEF MULTIPLIED, the X logo, NEVRO, and the NEVRO logo are
trademarks or registered trademarks of Nevro Corp. Patents covering
Senza HFX iQ and other Nevro products are listed at
Nevro.com/patents.
To learn more about Nevro, connect with us
on LinkedIn, Twitter, Facebook and Instagram.
1 World Health Organization. (2016). Global
report on diabetes. World Health Organization.
https://apps.who.int/iris/handle/10665/204871
2 Schmader K. E. (2002). Epidemiology and impact on
quality of life of postherpetic neuralgia and painful diabetic
neuropathy. The Clinical journal of
pain, 18(6),
350–354.
3 CDC National Diabetes
Statistics Report 2020.
4 Trinity Partners Market Research 2017.
Investors and Media:
Julie Dewey, IRC
Nevro
Corp.
Chief Corp Communications and Investor
Relations Officer
650-433-3247 |
julie.dewey@nevro.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nevro-announces-painful-diabetic-neuropathy-clinical-data-presentations-at-the-american-diabetes-association-83rd-scientific-sessions-301858570.html
SOURCE Nevro Corp.